Avui, dilluns 8 de juny, el Dipòsit Digital no estarà operatiu de 15:00 a 17:00 h per tasques de manteniment. Disculpeu les molèsties.
Hoy, lunes 8 de junio, el Dipòsit Digital no estará operativo de 15:00 a 17:00 h debido a tareas de mantenimiento. Disculpen las molestias.
Today, Monday, Jun 8th, the Digital Repository will be unavailable due to a system update.

Files

733409.pdf (270.4 KB)

Document type

Article

Version

Published version

Publication date

2022-02-11

Publication license

cc-by-nc-nd (c) Humbert, Marc et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/197012

Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1016/j.healun.2022.02.002

Abstract

EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study in patients with pulmonary hypertension treated with riociguat. Patients were followed for 1-4 years, and the primary outcomes were adverse events (AEs) and serious AEs (SAEs), including embolic/thrombotic and hemorrhagic events. Here we report data on patients with chronic thromboembolic pulmonary hypertension (CTEPH) receiving a vitamin K antagonist (VKA; n = 683) or a non-vitamin K antagonist oral anticoagulant (NOAC; n = 198) at baseline. AEs and SAEs were reported in 438 patients (64.1%) and 257 patients (37.6%), respectively, in the VKA group, and in 135 patients (68.2%) and 74 patients (37.4%) in the NOAC group. Exposure-adjusted hemorrhagic event rates were similar in the two groups, while exposure-adjusted embolic and/or thrombotic event rates were higher in the NOAC group, although the numbers of events were small. Further studies are required to determine the long-term effects of anticoagulation strategies in CTEPH.

Subject

Hipertensió pulmonar, Malalties cròniques, Anticoagulants (Medicina), Efectes secundaris dels medicaments, Vitamines K

Subject (English)

Pulmonary hypertension, Chronic diseases, Anticoagulants (Medicine), Drug side effects, Vitamin K

Citation

Collections

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citation

HUMBERT, Marc, et al. Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation. 2022. Vol. 41, num. 6, pags. 716-721. ISSN 1053-2498. [consulted: 8 of June of 2026]. Available at: https://hdl.handle.net/2445/197012

Export metadata

JSON - METS

Share record